4.7 Article

GBA-associated PD presents with nonmotor characteristics

期刊

NEUROLOGY
卷 77, 期 3, 页码 276-280

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318225ab77

关键词

-

资金

  1. European Community [241791]
  2. GlaxoSmithKline
  3. UCB
  4. Movement Disorders Society
  5. Novartis
  6. Merck Serono
  7. Schwarz Pharma
  8. Boehringer Ingelheim
  9. Valeant Pharmaceuticals International
  10. European Union
  11. BMBF (the Federal Ministry of Education and Research)
  12. Helmholtz Association
  13. Lundbeck Inc.
  14. UCB/Schwarz Pharma
  15. Johnson Johnson
  16. Teva Pharmaceutical Industries Ltd.
  17. Janssen
  18. Solvay Pharmaceuticals
  19. Inc./Abbott
  20. Michael J Fox Foundation
  21. dPV (German Parkinson's Disease Association)
  22. Center of Integrative Neurosciences
  23. BMBF

向作者/读者索取更多资源

Objective: To evaluate whether there exists distinct characteristics in glucocerebrosidase (GBA)-associated Parkinson disease (PD) with regard to motor and nonmotor symptoms as well as imaging characteristics assessed by transcranial sonography (TCS). Methods: Twenty patients with PD with heterozygous GBA mutations (N370S, L444P) (GBA-PD) in comparison to 20 patients with sporadic PD negative for GBA mutations (sPD) were included. We assessed motor impairment with the Unified Parkinson's Disease Rating Scale-III. Nonmotor symptoms were evaluated using the Montreal Cognitive Assessment, Neuropsychiatric Inventory, revised form of the Beck Depression Inventory, Parkinson Disease Sleep Scale, Sniffin' Sticks, and Unified Multiple System Atrophy Rating Scale items 9-12. TCS imaging was used to detect morphologic characteristics. Results: Patients with GBA-PD more often had a variety of nonmotor symptoms, namely dementia, neuropsychiatric disturbances, and autonomic dysfunction, and had more severe cases, than patients with sPD. They also demonstrated a higher prevalence of a reduced echogenicity of the brainstem raphe assessed by TCS. Conclusions: Especially nonmotor symptoms seem to be very common in GBA-PD. Further studies are needed to validate these observations in order to better understand the pathogenesis of GBA-PD and develop specific therapeutic concepts. Neurology (R) 2011;77:276-280

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据